Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nechaeva

Showing results (291-300 of 594) with videos related to

Pageof 60
Sort By:
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Photosynthesis Research|January 23, 2017
Membrane fluidity controls redox-regulated cold stress responses in cyanobacteriaEugene G Maksimov, Kirill S Mironov, Marina S Trofimova, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2024
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer|May 8, 2023
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3Tamta Makharadze, Ruben G W Quek, Tamar Melkadze, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 31, 2023
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialTamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
International Journal of Molecular Sciences|September 28, 2023
Heterologous <i>codA</i> Gene Expression Leads to Mitigation of Salt Stress Effects and Modulates Developmental ProcessesGalina N Raldugina, Lilia R Bogoutdinova, Olga V Shelepova, et al.
Topics in Current Chemistry (Cham)|March 19, 2026
Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer TherapyAnna M Nechaeva, Alexander A Artyukhov, Alina Yu Svistunova, et al.
Biomaterials Advances|October 24, 2024
Ultrasound protein-copolymer microbubble library engineering through poly(vinylpyrrolidone-co-acrylic acid) structureTatiana M Estifeeva, Anna M Nechaeva, Irina M Le-Deygen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2026
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 TrialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer Research Communications|July 17, 2024
Membrane-bound Heat Shock Protein mHsp70 Is Required for Migration and Invasion of Brain TumorsMaxim Shevtsov, Danila Bobkov, Natalia Yudintceva, et al.
Pageof 60

Showing results (291-300 of 594) with videos related to

Sort By:
Pageof 60
British Journal of Cancer|July 28, 2019
Correction: A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancerVera Gorbunova, J Thaddeus Beck, Ralf-Dieter Hofheinz, et al.
Photosynthesis Research|January 23, 2017
Membrane fluidity controls redox-regulated cold stress responses in cyanobacteriaEugene G Maksimov, Kirill S Mironov, Marina S Trofimova, et al.
Lung Cancer (Amsterdam, Netherlands)|May 31, 2024
Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer with PD-L1 ≥ 1 %: A subgroup analysis from the EMPOWER-Lung 3 part 2 trialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer|May 8, 2023
Quality of life with cemiplimab plus chemotherapy for first-line treatment of advanced non-small cell lung cancer: Patient-reported outcomes from phase 3 EMPOWER-Lung 3Tamta Makharadze, Ruben G W Quek, Tamar Melkadze, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|March 31, 2023
Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 TrialTamta Makharadze, Miranda Gogishvili, Tamar Melkadze, et al.
International Journal of Molecular Sciences|September 28, 2023
Heterologous <i>codA</i> Gene Expression Leads to Mitigation of Salt Stress Effects and Modulates Developmental ProcessesGalina N Raldugina, Lilia R Bogoutdinova, Olga V Shelepova, et al.
Topics in Current Chemistry (Cham)|March 19, 2026
Nanoparticles for Doxorubicin Delivery: Advances in Carrier Design and Synergistic Cancer TherapyAnna M Nechaeva, Alexander A Artyukhov, Alina Yu Svistunova, et al.
Biomaterials Advances|October 24, 2024
Ultrasound protein-copolymer microbubble library engineering through poly(vinylpyrrolidone-co-acrylic acid) structureTatiana M Estifeeva, Anna M Nechaeva, Irina M Le-Deygen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|June 15, 2026
Cemiplimab Plus Chemotherapy Versus Chemotherapy in Advanced NSCLC: 5-year Results From Phase 3 EMPOWER-Lung 3 Part 2 TrialAna Baramidze, Tamta Makharadze, Miranda Gogishvili, et al.
Cancer Research Communications|July 17, 2024
Membrane-bound Heat Shock Protein mHsp70 Is Required for Migration and Invasion of Brain TumorsMaxim Shevtsov, Danila Bobkov, Natalia Yudintceva, et al.
Pageof 60